Clinical Trial Update: Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab [Phase 2]

View source ↗

Summary

The Phase 2 trial of regorafenib as a single agent in patients with metastatic colorectal cancer carrying RAS or BRAF mutations, previously treated with FOLFOXI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Conditions: Colorectal Neoplasms, Metastatic Disease | Phase 2 | Status: TERMINATED